Overview

Price chart · mood · technical indicators

VNRX

Volitionrx Ltdstock Healthcare

Medical Devices

$2.3977.03%Current Market Mood:Strong Bearish

Market Mood

Price Range (1Y)

$2.36$18.80

Current: $2.39

Market Comparison

vs Healthcare Sector & Medical Devices Industry

VNRX

-77.03%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—Forward 10.53

EPS (TTM)$-4.400.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$19.3MMicro cap

Wall Street coverage

$29.21median target· current $15.59 (+87.4%)5 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 10.53
PEG ratio: 0.00
P/B: 38.44
P/S (TTM): 11.15
EV/EBITDA: -1.43

Profitability & growth

ROE (TTM): -730.0%
Operating margin: -1078.0%
Revenue growth YoY: 133.2%
Dividend yield: —
Beta: 1.33

Last earnings

Mar 31, 2026 · Estimate $-0.05 · Reported $-0.05

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Volitionrx Ltd

Company profile

VolitionRx Limited, a multinational epigenetics company, is dedicated to developing blood tests to help diagnose a variety of cancers and other diseases globally. The company is headquartered in Austin, Texas.

Classification

Sector: Healthcare
Industry: Medical Devices
Exchange: NYSE MKT
Country: USA
Currency: USD

Company profile

HQ: 1489 WEST WARM SPRINGS ROAD, HENDERSON, NV
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$19.3M

Shares outstanding$7.9M

52W high$18.80

52W low$2.36

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

VNRX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

VolitionRx Limited 2025 Annual Report: Executive Compensation, Director Ownership, and Corporate Governance Insights

CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX)

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Limited Announces Amendment to Certificate of Incorporation in April 2026 8-K Filing

VolitionRx Enacts One-for-Twenty Reverse Stock Split

VolitionRx (NYSE: VNRX) implements 1-for-20 reverse stock split

VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing

VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard

VolitionRx shares stay on NYSE as exchange accepts compliance plan

VolitionRx receives NYSE American compliance plan approval

VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside?

VNRX Downgraded by D. Boral Capital -- Rating Changed to Hold

VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside?

After building for 10 years, Volition puts nucleosomes up for sale online

VolitionRx Ltd stock (US92852X1037): Is its blood-testing breakthrough strong enough to unlock inves

VolitionRx (VNRX) to execute 1-for-20 reverse stock split on April 28, 2026

VNRX Should I Buy

VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S.

VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S.

VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript

About Volitionrx Ltd

Classification

Company profile

VNRX

Market Comparison

VNRX Market Analysis

Overview

VNRX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

VolitionRx Limited 2025 Annual Report: Executive Compensation, Director Ownership, and Corporate Governance Insights

CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX)

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Limited Announces Amendment to Certificate of Incorporation in April 2026 8-K Filing

VolitionRx Enacts One-for-Twenty Reverse Stock Split

VolitionRx (NYSE: VNRX) implements 1-for-20 reverse stock split

VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing

VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard

VolitionRx shares stay on NYSE as exchange accepts compliance plan

VolitionRx receives NYSE American compliance plan approval

VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside?

VNRX Downgraded by D. Boral Capital -- Rating Changed to Hold

VolitionRx Ltd stock (US92852X1037): Does its blood-testing tech unlock real diagnostic upside?

After building for 10 years, Volition puts nucleosomes up for sale online

VolitionRx Ltd stock (US92852X1037): Is its blood-testing breakthrough strong enough to unlock inves

VolitionRx (VNRX) to execute 1-for-20 reverse stock split on April 28, 2026

VNRX Should I Buy

VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S.

VolitionRx Ltd stock (US92852X1037): Why does its blood-testing innovation matter more now for U.S.

VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript

About Volitionrx Ltd

Classification

Company profile

VNRX

Market Comparison